JP2012524112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524112A5 JP2012524112A5 JP2012506296A JP2012506296A JP2012524112A5 JP 2012524112 A5 JP2012524112 A5 JP 2012524112A5 JP 2012506296 A JP2012506296 A JP 2012506296A JP 2012506296 A JP2012506296 A JP 2012506296A JP 2012524112 A5 JP2012524112 A5 JP 2012524112A5
- Authority
- JP
- Japan
- Prior art keywords
- klk
- pharmaceutical composition
- seq
- polypeptide
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17118909P | 2009-04-21 | 2009-04-21 | |
| US61/171,189 | 2009-04-21 | ||
| PCT/CA2010/000561 WO2010121358A1 (en) | 2009-04-21 | 2010-04-21 | Tissue kallikrein for the treatment of schizophrenia and bipolar disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012524112A JP2012524112A (ja) | 2012-10-11 |
| JP2012524112A5 true JP2012524112A5 (enExample) | 2013-05-30 |
Family
ID=43010629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506296A Pending JP2012524112A (ja) | 2009-04-21 | 2010-04-21 | 統合失調症および双極性障害を治療するための組織カリクレイン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120201804A1 (enExample) |
| EP (1) | EP2421553A4 (enExample) |
| JP (1) | JP2012524112A (enExample) |
| CN (1) | CN102458453A (enExample) |
| CA (1) | CA2759481A1 (enExample) |
| WO (1) | WO2010121358A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582930A (en) | 2007-07-20 | 2012-11-30 | Diamedica Inc | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| PT2854841T (pt) | 2012-06-04 | 2017-05-15 | Diamedica Inc | Isoformas de glicosilação da calicreína 1 em tecido humano |
| EP3305325B1 (en) * | 2015-06-04 | 2025-07-30 | National Center of Neurology and Psychiatry | Mental illness therapeutic agent having il-6 inhibitor as active ingredient |
| ES3001152T3 (es) | 2016-12-20 | 2025-03-04 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| US11857608B2 (en) | 2017-03-09 | 2024-01-02 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| EP3810099A1 (en) | 2018-06-20 | 2021-04-28 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN109091667B (zh) * | 2018-09-18 | 2020-05-05 | 广东天普生化医药股份有限公司 | 人尿激肽原酶在制备治疗偏头痛药物中的用途及其组合物 |
| CN116549619A (zh) * | 2022-01-28 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 激肽原酶及其衍生物在治疗vci、psci或csvd中的应用 |
| CN116554267A (zh) * | 2022-01-30 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇修饰的激肽或其变体和药物应用 |
| CN116549599A (zh) * | 2022-01-30 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 激肽及其衍生物在治疗vci、psci或csvd中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582930A (en) * | 2007-07-20 | 2012-11-30 | Diamedica Inc | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| WO2010009557A1 (en) * | 2008-07-25 | 2010-01-28 | Sanomune Inc. | Tissue kallikrein for the treatment of parkinson's disease |
-
2010
- 2010-04-21 JP JP2012506296A patent/JP2012524112A/ja active Pending
- 2010-04-21 EP EP10766544A patent/EP2421553A4/en not_active Withdrawn
- 2010-04-21 WO PCT/CA2010/000561 patent/WO2010121358A1/en not_active Ceased
- 2010-04-21 CN CN2010800272716A patent/CN102458453A/zh active Pending
- 2010-04-21 CA CA2759481A patent/CA2759481A1/en not_active Abandoned
-
2011
- 2011-10-21 US US13/278,933 patent/US20120201804A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2012041342A5 (enExample) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| MX2011008616A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| BR112014016085A8 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| JP2011225596A5 (enExample) | ||
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| UA92453C2 (ru) | Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2014515408A5 (enExample) | ||
| RU2014122858A (ru) | Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями | |
| UA110463C2 (ru) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я | |
| JP2011513437A5 (enExample) | ||
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2018528259A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| BR112014004339A2 (pt) | suspensão oral | |
| JP2016504361A5 (enExample) |